Takagi Kentaro, Tamura Atsushi, Hayasaka Junnosuke, Watanabe Ayako, Okamoto Eiko, Kusano-Kitazume Akiko, Kondo Mayumi, Shibayama Takao, Suenobu Yutaka, Ohtaka Yoshiko, Akita Hidetaka, Tei Shikofumi
Dept. of Gastroenterology, Tokyo Metropolitan Toshima Hospital.
Gan To Kagaku Ryoho. 2014 Nov;41(12):2490-2.
A standard treatment for primary peritoneal carcinoma has not been established to date. We describe a case in which this cancer was successfully treated by use of paclitaxel and carboplatin chemotherapy.
An 80-year-old woman who presented with abdominal distension and right upper abdominal pain was diagnosed with massive ascites and an omentum tumor via abdominal computed tomography and magnetic resonance imaging (MRI); her ovaries were normal-sized. Serum levels of the tumor marker CA125 were above normal (170 U/mL), and aspiration cytology showed the presence of adenocarcinoma cells. Despite several examinations, the primary tumor was not detected. The patient underwent exploratory laparotomy and was diagnosed with primary peritoneal carcinoma. She received combination chemotherapy consisting of paclitaxel and carboplatin. Serum CA125 levels returned to normal, and an MRI showed no evidence ofa tumor.
Paclitaxel and carboplatin combination chemotherapy is effective for treatment of primary peritoneal adenocarcinomas.
原发性腹膜癌的标准治疗方法至今尚未确立。我们描述了一例通过使用紫杉醇和卡铂化疗成功治疗该癌症的病例。
一名80岁女性，出现腹胀和右上腹疼痛，经腹部计算机断层扫描和磁共振成像（MRI）诊断为大量腹水和网膜肿瘤；她的卵巢大小正常。肿瘤标志物CA125的血清水平高于正常（170 U/mL），抽吸细胞学检查显示存在腺癌细胞。尽管进行了多项检查，但未检测到原发性肿瘤。患者接受了剖腹探查术，被诊断为原发性腹膜癌。她接受了由紫杉醇和卡铂组成的联合化疗。血清CA125水平恢复正常，MRI显示无肿瘤迹象。
紫杉醇和卡铂联合化疗对原发性腹膜腺癌的治疗有效。
